stoxline Quote Chart Rank Option Currency Glossary
  
FibroGen, Inc. (FGEN)
0.5545  0.034 (6.47%)    02-14 16:00
Open: 0.53
High: 0.594
Volume: 1,352,745
  
Pre. Close: 0.5208
Low: 0.5134
Market Cap: 56(M)
Technical analysis
2025-02-14 4:48:03 PM
Short term     
Mid term     
Targets 6-month :  0.75 1-year :  0.88
Resists First :  0.64 Second :  0.75
Pivot price 0.49
Supports First :  0.52 Second :  0.45
MAs MA(5) :  0.5 MA(20) :  0.49
MA(100) :  0.42 MA(250) :  0.85
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  52.5 D(3) :  38.8
RSI RSI(14): 58.8
52-week High :  2.79 Low :  0.18
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ FGEN ] has closed Bollinger Bands are 37.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.6 - 0.6 0.6 - 0.6
Low: 0.51 - 0.51 0.51 - 0.51
Close: 0.55 - 0.55 0.55 - 0.56
Company Description

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Headline News

Tue, 21 Jan 2025
FibroGen (NASDAQ:FGEN) Share Price Passes Above 50-Day Moving Average - What's Next? - MarketBeat

Wed, 25 Dec 2024
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 26% Share Price Rise - Simply Wall St

Wed, 18 Dec 2024
FibroGen started at buy by H.C. Wainwright (FGEN:NASDAQ) - Seeking Alpha

Mon, 16 Dec 2024
FibroGen Appoints David DeLucia as Chief Financial Officer - GlobeNewswire

Mon, 16 Dec 2024
FibroGen Names David DeLucia as New CFO to Lead Financial Strategy and Drug Development Push - StockTitan

Wed, 13 Nov 2024
FGEN stock touches 52-week low at $0.19 amid market challenges - Investing.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 101 (M)
Shares Float 91 (M)
Held by Insiders 0.8 (%)
Held by Institutions 55 (%)
Shares Short 4,320 (K)
Shares Short P.Month 4,540 (K)
Stock Financials
EPS -1.24
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -2.07
Profit Margin -96.9 %
Operating Margin -21.6 %
Return on Assets (ttm) -26.6 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 14.3 %
Gross Profit (p.s.) -0.6
Sales Per Share 1.72
EBITDA (p.s.) -1.65
Qtrly Earnings Growth 0 %
Operating Cash Flow -202 (M)
Levered Free Cash Flow -122 (M)
Stock Valuations
PE Ratio -0.46
PEG Ratio 0
Price to Book value -0.27
Price to Sales 0.32
Price to Cash Flow -0.28
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android